Clinical Trial: Sacituzumab Govitecan in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674615) titled 'Sacituzumab Govitecan in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer' on June 24.

Brief Summary: To observe the efficacy and safety of sacituzumab govitecan in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Epithelial Ovarian Cancer Fallopian Tube Cancers Primary Primary Peritoneal Carcinoma

Intervention: DRUG: Sacituzumab govitecan monotherapy

Sacituzumab govitecan monotherapy at a dose of 10 mg/kg administered intravenousl...